Christina Baik, MD
Dr. Christina Baik is a medical oncologist at Fred Hutchinson Cancer Center and Clinical Research Director of Thoracic, Head, and Neck Oncology at UW Medicine in Seattle, Washington. Her specialties include the treatment of lung cancer and malignant pleural mesothelioma, as well as head and neck cancers, endocrine tumors, oral cancer, and salivary gland cancer.[1]
Dr. Baik is working to develop effective targeted therapies for these illnesses. She sees caring for cancer patients as a privilege and tries to bring grace and generosity to her work.
Education and Career
Dr. Baik attended the University of Puget Sound as an undergraduate, then moved on to earn her medical degree from the University of Rochester School of Medicine. She completed her internship and residency in General Internal Medicine at Brown Medical School and finished her medical training with a fellowship in Hematology and Oncology at Tufts Medical Center. She is board-certified in Oncology and General Internal Medicine by the American Board of Internal Medicine. She also earned her Master of Public Health degree from the Harvard School of Public Health and has completed a post-doctoral research fellowship at the Fred Hutchinson Cancer Research Center.[1]
Research
Dr. Baik is an active researcher with a focus on developing effective targeted therapies for people with oncogene-driven lung cancer and understanding the mechanisms of primary and secondary resistance to immunotherapy. She is also dedicated to finding ways to detect more lung cancers in their earlier stages, when they are more manageable.[1]
Her recent publications include:[3]
- HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies.Uy NF, Merkhofer CM, Baik CS.Cancers (Basel). 2022 Aug 27;14(17):4155. doi: 10.3390/cancers14174155.PMID: 36077691 Free PMC article. Review.
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V.Lancet Oncol. 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. Epub 2021 Jun 9.PMID: 34118197 Clinical Trial.
- Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D’Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.PMID: 27283860 Clinical Trial.
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH.Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9.PMID: 34118198 Clinical Trial.
- New Immuno-oncology Targets and Resistance Mechanisms.Tokaz MC, Baik CS, Houghton AM, Tseng D. Curr Treat Options Oncol. 2022 Sep;23(9):1201-1218. doi: 10.1007/s11864-022-01005-8. Epub 2022 Aug 18.PMID: 35980521 Review.
- Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM.Clin Cancer Res. 2017 Sep 1;23(17):4992-5002. doi: 10.1158/1078-0432.CCR-16-3066.PMID: 28864727
Her active clinical trials include:[2]
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naive EGFR-mutant Locally Advanced or Metastatic NSCLC. Trial phase: II
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1) Trial Phase: I/II
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Trial phase: I/II
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Trial phase: I/II
